BACE-1 Study for patients with Mild Cognitive Impairment

The Merck BACE-1 Study is a Phase III study for patients with Mild Cognitive Impairment testing the safety, tolerability and cognitive effects of the Merck BACE inhibitor drug. This study is for individuals 50-85 years of age with a diagnosis of mild cognitive impairment.

This drug is not FDA approved and is investigational. As a BACE inhibitor, the drug inhibits the enzyme that produces beta amyloid plaques, deposits of which accumulate in the brains of patients with Alzheimer’s disease. The study will assess the effects of the drug on cognition and the ability to perform everyday activities.

Participants must have a reliable study partner: a spouse, relative, or friend who knows the participant well and sees him or her often, who will attend all study visits, and who will provide information about the participant during the study.

Download a one-page overview of this study including contact information